BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales

On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime opportunity.” To him, the company’s potential in chronic lymphocytic leukemia is akin to two other legendary Big Biotech stories—Gilead in HIV and Vertex in cystic fibrosis.